Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Gastrointestinal
Study Name
EA2165: Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Principal Investigator
Gordan Srkalovic MD, PhD
Study Information
https://www.clinicaltrials.gov/ct2/show/NCT03233711?term=EA2165&rank=1
Contact for Questions
Nurse - Tracy 517-364-2835

Site view: at a glance